It's Time for Clorotekal®

Product Quick Finder

Choose a category or subcategory

The Only FDA-Approved Chloroprocaine Hydrochloride Indicated for Spinal Anesthesia

Indications: Clorotekal®* (chloroprocaine hydrochloride) is indicated for intrathecal injection for the production of subarachnoid block (spinal anesthesia) in adults undergoing surgical procedures. Indicated procedures include those suitable for CLOROTEKAL’s short duration of action.

Contraindications: Known hypersensitivity to the active substance, medicinal products of the PABA (para-aminobenzoic acid) ester group, other ester-type local anesthetics or to any of the excipients. General and specific contraindications to spinal anesthesia regardless of the local anesthetic used should be taken into account (e.g., decompensated cardiac insufficiency, hypovolemic shock, coagulopathy). Intravenous regional anesthesia (the anesthetic agent is introduced into the limb and allowed to set in while tourniquets retain the agent within the desired area). Serious problems with cardiac conduction. Local infection at the site of proposed lumbar puncture and Septicemia.

*Clorotekal is a registered trademark of Sintetica S.A. and is manufactured for B. Braun Medical Inc. 

A Closer Look at Clorotekal

ESTER LOCAL ANESTHETIC

PRESERVATIVE-FREE: Clorotekal is formulated without sodium bisulfate or methylparaben.

RAPID ONSET: Clorotekal has a rapid onset of action, usually 6 to 12 minutes.

SHORT DURATION OF ACTION

ISOBARIC SOLUTION: Range of relative density 1.0070 - 1.0080 g/g

EXAMPLES OF SURGICAL PROCEDURES THAT MAY BE SUITABLE FOR CLOROTEKAL’S SHORT DURATION OF ACTION

For a complete list of references referer to the end of the page

Clinical Studies of 1% Chloroprocaine

Study Design:

  • Study 1 was a phase 2 single-center, prospective, randomized, observer-blinded study.
  • Evaluated the efficacy and the tolerability of 1% chloroprocaine in three doses 30, 40, and 50 mg after spinal injection.
  • In 45 adult patients undergoing short duration (<40 minutes) lower limb surgery.

Efficacy Results:

  • Neither rescue anesthesia nor rescue analgesia was required for subjects randomized to chloroprocaine 50 mg.
  • Three subjects in the 30 mg dose group and three subjects in the 40 mg dose group required intraoperative rescue medications.
  • Doses above 50 mg have not been adequately tested for efficacy and safety.
*Spinal anesthesia with Chloroprocaine HCl 1% for elective lower limb procedures of short duration: a prospective, randomized, observer-blinded study in adult patients.

Study Design:

  • Study 2 was a phase 3, multicenter, prospective, randomized, observer-blinded study.
  • Evaluated the safety and efficacy of 50 mg of chloroprocaine 10 mg/mL in intrathecal anesthesia versus 10 mg of bupivacaine 0.5%.
  • In 130 adult patients undergoing short duration (<40 minutes) low abdominal surgery (gynecological or urological) and lower limb surgery.
  • Each patient received a single dose of anesthetic: 50 mg of chloroprocaine or 10 mg of bupivacaine.

Efficacy Results:

  • Efficacy was determined by the proportion of patients who were able to complete the surgical procedure without the need for rescue intravenous analgesic or sedation drugs.
  • Efficacy results proved that 6 of 66 subjects (9%) in the chloroprocaine group required rescue compared to 6 of 64 (9%) in the bupivacaine group.
*Prospective, observer-blinded, randomized clinical study to investigate and compare the efficacy of intrathecal plain solutions containing Chloroprocaine 1% (50 mg) versus Bupivacaine 0.5% (10mg)

One Solution - Many Benefits

Product Details

Product Size:

50mg/5mL

NDC#

0264-7055-10

Clorotekal Contact

B. Braun Medical Inc. Medical Affairs Specialists

If you are a healthcare professional requiring medical information on Clorotekal, please contact:
You are encouraged to report negative side effects of prescribed drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

CLOROTEKAL® (chloroprocaine hydrochloride) is a prescription drug indicated for intrathecal injection for the production of subarachnoid block (spinal anesthesia) in adults undergoing surgical procedures. Indicated procedures include those suitable for Clorotekal’s short duration of action.

CONTRAINDICATIONS

Known hypersensitivity to the active substance, medicinal products of the PABA (para-aminobenzoic acid) ester group, other ester-type local anesthetics or to any of the excipients. General and specific contraindications to spinal anesthesia regardless of the local anesthetic used should be taken into account (e.g., decompensated cardiac insufficiency, hypovolemic shock, coagulopathy). Intravenous regional anesthesia (the anesthetic agent is introduced into the limb and allowed to set in while tourniquets retain the agent within the desired area). Serious problems with cardiac conduction. Local infection at the site of proposed lumbar puncture and Septicemia.

DOSAGE AND ADMINISTRATION

CLOROTEKAL is intended for single-dose administration only. To obtain an effective block to the T 10 level with one single administration in an adult of average height and weight (approximately 70 kg), the recommended dose is 50 mg (5 mL).

WARNINGS AND PRECAUTIONS

Risks with Neuraxial Administration: Local anesthetics should only be administered after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. Cardiovascular System Reactions: hypotension and bradycardia. Central Nervous System Reactions: paresthesia, loss of sensitivity, motor weakness, paralysis, cauda equina syndrome and permanent neurological injury. Allergic Reactions: in patients with a known hypersensitivity to the active substance or to other formulation ingredients. Chondrolysis: in intra-articular infusions in arthroscopic and other surgical procedures.

ADVERSE REACTIONS

Adverse reactions reported with an incidence greater than or equal to 2 % following CLOROTEKAL administration are procedural pain, injection site pain and hypotension. To report SUSPECTED ADVERSE REACTIONS, contact B. Braun Medical Inc. at 1-800-854-6851 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

• Vasopressor and Ergot-Type Oxytocic Drugs: May cause severe, persistent hypertension or cerebrovascular accidents. Avoid concurrent administration.

• Sulfonamide Drugs: Avoid use in any condition in which a sulfonamide drug is being employed.

• Antiarrhythmics: No studies have been performed on interactions between chloroprocaine and class III antiarrhythmics (e.g. amiodarone).

• Local Anesthetics: Avoid combination of various local anesthetics.

REFERENCES:

1 Tunçalp Ö, Gülmezoglu AM, Souza JP. Surgical procedures for evacuating incomplete miscarriage. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD001993. DOI: 10.1002/14651858. CD001993.pub2.
2 Solmaz, F.A., Kovalak, E. (2018). Comparison of tramadol/acetaminophen fixed-dose combination, tramadol, and acetaminophen in patients undergoing ambulatory arthroscopic meniscectomy. Acta Orthopaedica et Traumatologica Turcica, 52, 222-225.
3 Edelman, D.S. (2017). Robotic Inguinal Hernia Repair. The American Surgeon, 83(12), 1418-1421.
4 Lin, P.H., et al. (2016). Treatment Outcomes and Lessons Learned From Transilluminated Powered Phlebectomy for Varicose Veins in 1034 Patients. Vascular and Endovascular Surgery, 50(4), 277-282.
5 Hamdy, A.A., et al. (2018). Conventional Hemorrhoidectomy versus Ligasure Hemorrhoidectomy: A Comparative Study. The Egyptian Journal of Hospital Medicine, 71(5), 3116-3120.
6 Murtaza, G., et al. (2017). Fistulotomy versus fistulectomy for simple fistula in ano: a retrospective cohort study. The Journal Of The Pakistan Medical Association, 67(3), 339-342.
7 Xu, Y., et al. (2016). Meta-analysis of randomized clinical trials comparing fistulectomy versus fistulotomy for low anal fistula. Springerplus, 5, 1-6. doi:10.1186/s40064-016-3406-8
8 Hiramatsu, K., et al. (2013). Conization using the Shimodaira-Taniguchi procedure for adenocarcinoma in situ of the uterine cervix. European Journal of Obstetrics & Gynecology and Reproductive Biology, 168, 218-221.
9 Chua, A.A.A., et al. (2016). The application of hysteroscopy in gestational trophoblastic disease. Gynecology and Minimally Invasive Therapy, 5, 30-32.
10 Shirvan, M.K., et al. (2014). Tension-free vaginal tape versus transobturator tape for treatment of stress urinary incontinence: A comparative randomized clinical trial study. Urological Science, 25, 54-57.
11 Leathersich, S.J., McGurgan, P.M. (2018). Endometrial resection and global ablation in the normal uterus. Best Practice & Research Clinical Obstetrics and Gynaecology, 46, 84-98.
12 Peng, Y., Cheng, Y., Wang, G., Wang, S., Jia, C., Yang, B., Geng, D. (2008). Clinical application of a new device for minimally invasive circumcision. Asian Journal of Andrology, 10(3), 447-454.
13 Shah, J., et al. (2002). Validation of a flexible cystoscopy course. BJU International, 90, 833-835.
14 Olcese, S.P., et al. (2014). Comparison of outcomes after TURP versus photoselective vaporization of the prostate with respect to trainee involvement utilizing ACS NSQIP. Prostate Cancer and Prostatic Disease, 17, 228.